Trial Profile
A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) With Placebo in Achieving Remission in Patients With Active Lupus Nephritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Jan 2024
Price :
$35
*
At a glance
- Drugs Voclosporin (Primary) ; Corticosteroid; Methylprednisolone; Prednisone
- Indications Lupus nephritis
- Focus Registrational; Therapeutic Use
- Acronyms AURA; AURA-LV
- Sponsors Aurinia Pharmaceuticals
- 15 Nov 2023 Results of pooled analysis of Phase 2 AURA-LV and Phase 3 AURORA 1 studies assessing outcomes in patients with UPCR >-2 g/g, presented at the ACR Convergence 2023.
- 07 Nov 2023 According to an Aurinia Pharmaceuticals media release, data from this study will be presented at the annual American College of Rheumatology Convergence 2023
- 07 Nov 2023 Results of post-hoc, pooled analysis of the Phase 2 AURA-LV and Phase 3 AURORA 1 studies presented in the Aurinia Pharmaceuticals Media Release